2:44 PM, May 23, 2012
TORONTO, ONTARIO -- Trimel Pharmaceuticals Corporation today announced the initiation of patient enrollment into one of the largest clinical studies to ever explore a "use-as-required" treatment for women experiencing anorgasmia. Anorgasmia is defined as the persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase which can result in marked personal distress or interpersonal difficulties.
Anorgasmia affects 1 in 5 pre and post menopausal women worldwide. Currently there are no approved treatments for FOD and therefore represents an unmet need for women suffering distress from this condition.
The Company intends to enroll 240 patients in this Phase II study being initiated in the United States, with additional sites in Canada and Australia expected to join the study in the third quarter of 2012.
The principal investigator for this study is Dr. Sheryl Kingsberg. Dr. Kingsberg is the Chief of Behavioral Medicine at University Hospitals Case Medical Center and Professor in Reproductive Biology and Psychiatry at Case Western Reserve University in Cleveland, Ohio. Dr. Kingsberg's primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause.
For more information, call 440-995-3810.